Compare Marqeta Inc (MQ) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Sana Biotechnology Inc — how do they compare? Marqeta Inc trades at $18.09 (market cap $1.82B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Marqeta Inc is far larger — about 2.2× Sana Biotechnology Inc's market cap, and Marqeta Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Marqeta Inc for 44 Days and Sana Biotechnology Inc for 23 Days on average.
| MQ | SANA | |
|---|---|---|
Market Cap | $1.82B | $836.71M |
Volume | 1,126,466 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $20.32 | $5.92 |
52-Week Low | $15.04 | $2.68 |
Typical Hold Time | 44 Days | 23 Days |
Enterprise Value | $1.13B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $18.11, up 6.15% with a bullish technical signal. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, while revenue grew 23% year-over-year to $625M in 2025. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic expansion. However, valuation remains elevated with a P/E of 193.83 and negative EBITDA of -$19.27M despite improving cash flow trends.
Outlook remains mixed with analyst consensus at Hold (59% of ratings) and a $11.38 price target suggesting 37% downside. Key risks include contract renewals in Q3 2026 potentially slowing growth, while institutional sentiment is cautious despite technical strength. The stock's premium valuation requires sustained execution to justify current levels.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
